A carregar...
Managing bone mineral density with oral bisphosphonate therapy in women with breast cancer receiving adjuvant aromatase inhibition
The use of adjuvant aromatase inhibitors is associated with an increased risk of osteoporosis and fractures. The oral bisphosphonate, risedronate - dosed as the US Food and Drug Administration approved for the treatment or prevention of postmenopausal osteoporosis - appears to mitigate bone loss ass...
Na minha lista:
| Autor principal: | |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2010
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2917025/ https://ncbi.nlm.nih.gov/pubmed/20584345 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/bcr2584 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|